OrbiMed Genesis GP LLC
CIK 1808744 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$865.19M
Companies
14
Total Filings
24
Lifetime Open-Market Net
-$29.17M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STTK | Director | 1,051,021 | $6.82 | $7.17M | $0 | 2 | 2026-06-15 |
| QTTB | Director | 625,000 | $15.71 | $9.82M | $45.00M | 1 | 2026-06-01 |
| IMA | Director | 753,062 | $5.76 | $4.34M | $0 | 2 | 2026-04-16 |
| EWTX | Director | 14,809,075 | $40.35 | $597.55M | $30.00M | 1 | 2025-04-04 |
| IRON | Director | 746,171 | $74.65 | $55.70M | -$12.57M | 2 | 2025-03-26 |
| IMRA | Director | 7,663,349 | $14.49 | $111.04M | -$68.63M | 2 | 2024-05-20 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 2,270,930 | $64.97 | $147.54M | -$86.02M | 1 | 2023-12-29 |
| PMVP | 10%+ Owner | 6,475,291 | $1.10 | $7.12M | -$587.3K | 1 | 2023-11-24 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 25,242 | $28.69 | $724.2K | -$5.44M | 4 | 2023-08-17 |
| CMPX | Director | 15,219,994 | $2.04 | $31.05M | $5.13M | 2 | 2022-11-10 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 0 | $54.99 | $0 | $0 | 1 | 2022-07-01 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 174,841 | $17.16 | $3.00M | -$3.38M | 1 | 2022-06-24 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 16,384,235 | $4.06 | $66.52M | $31.33M | 2 | 2022-01-13 |
| JANX | Director | 2,760,366 | $15.00 | $41.41M | $36.00M | 1 | 2021-06-16 |
Recent Filings · Page 2 of 3
24 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-24 | PMVP | Sell (S) | −263,358 | -$587.3K | EDGAR |
| 2023-08-17 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −4,113,400 | -$3.09M | EDGAR |
| 2023-04-17 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −342,405 | -$641.3K | EDGAR |
| 2023-04-12 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −337,685 | -$606.8K | EDGAR |
| 2023-04-07 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −513,150 | -$1.11M | EDGAR |
| 2023-02-27 | IMRA | Grant (A) | +23,698,716 | $0 | EDGAR |
| 2023-01-03 | — | Other (J) | +8,643,764 | $0 | |
| 2022-11-10 | CMPX | Buy (P) | +1,206,000 | $3.87M | EDGAR |
| 2022-07-01 | Sierra Oncology, Inc. (SRRA) Delisted | Disp (D) | −7,859,080 | -$432.25M | EDGAR |
| 2022-06-24 | ImageneBio, Inc. (IKNA) Delisted | Buy (P) | −756,675 | -$3.38M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.